

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY,
IN AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE UNITED STATES**

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

The investment or investment activity related to the Company is available only to persons falling within the category of professional investors under the MIFID (the "Exempted Persons") and will be engaged in only with the Exempted Persons.

Investors should not subscribe for any securities referred to in this document except on the basis of information contained in the prospectus.

In any EEA Member State that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive. The expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in any relevant Member State) and includes any relevant implementing measure in the relevant Member State.

PRESS RELEASE

COMPLETION OF THE SALE OF GENERAL MEDICAL MERATE S.P.A. GENERATING A CAPITAL GAIN OF €2.2 MILLION FOR NB AURORA

- **GENERAL MEDICAL MERATE S.P.A. EXIT FOLLOWS RECENT EXITS FROM MESGO, MEGADYNE, TRUESTAR, IEN, SANLORENZO AND RIGONI DI ASIAGO BY FONDO ITALIANO DI INVESTIMENTO ("FII")**
- **THE TOTAL CAPITAL GAIN GENERATED FOR NB AURORA FROM FII REALISATIONS INCREASED TO €34.2 MILLION SINCE 30 JUNE 2018**

Luxembourg, November, 15 2018

NB Aurora S.A. SICAF-RAIF ("NB Aurora"), a fund listed in Italy on the MIV professional segment of the Italian Stock Exchange, organized and managed by Borsa Italiana S.p.A., with the aim of acquiring minority stakes in Italian unlisted SMEs, announces that today, with reference to the 44.55% interest held by NB Aurora in Fondo Italiano di Investimento (FII) and following the press release distributed on October 30, 2018, FII has completed the sale of its entire shareholding in General Medical Merate S.p.A. (GMM).

The 28.85% stake held by FII in GMM is acquired jointly by the Sordi family and Kangda Medical Equipment Group Co. Limited, the GMM's long-standing Chinese partner, though the Sordi family remains the majority shareholder of GMM.

The realization proceeds of NB Aurora's indirect participation in GMM, through FII, was equal to €8.6 million (€0.5 million of which was funded in May 2018 and the balance of €8.1 million was funded at today's closing). The capital gain generated for NB Aurora amounted to €2.2 million.

GMM, a company founded in 1952 and headquartered in Seriate (Bergamo) is a member of Borsa Italiana's ELITE program since 2012, and operates in the production and sale of radiological equipments, employing about 300 people with an annual turnover of €83.6 million.

FII is proceeding with its disinvestments program and the capital gains generated for NB Aurora increased to a total of €34.2 million, thanks to the disposals realized since 30 June 2018. The residual fair market value of the portfolio as of 30 September 2018 is approximately €64.5 million, gross of the Net Other Assets, amounting to approximately €1.0 million as of 30 June 2018.

Since 30 June 2018 and without considering the sale of GMM, FII has already distributed approximately €60.6 million to NB Aurora compared to the €75.4 million paid by NB Aurora for the purchase of 44.55% of the shares in FII. The approximately additional €8 million generated from the sale of the stake held in GMM will be distributed by the end of the year, increasing the total distributions to NB Aurora to approximately €68.6 million.

Francesco Sogaro, Managing Director at Neuberger Berman, commented: "We are particularly proud of the growth path achieved in these years together with the Sordi family. GMM can be considered one of the historical Italian companies that over the years has achieved a leading position in the field of diagnostic radiology machines, acting as a reference point for the entire sector at both a national and international level. What we did for GMM represents an example of the success of NB Aurora's philosophy, that is to guide and support visionary and successful entrepreneurs to accelerate their development projects both domestically and internationally".

Massimo Sordi, GMM Chairman, added "The Sordi family and all the shareholders, as NB Aurora leaves the General Medical Merate shareholder base, thank Francesco Sogaro and the entire NB Aurora team, formerly Fondo Italiano di Investimento, for their support in these years of collaboration, when there has been an acceleration in the process of both organic and external growth of GMM. It has been

an exciting path, which still continues and that has affirmed our company in the field of medical radiology, in Italy and worldwide. At the end of this period of collaboration, we now move towards another step allowing the whole team of GMM to take advantage of what has been learned from the experience with FII and NB Aurora and, why not, to replicate this fruitful partnership in the future and in other forms”.

NB Aurora and FII are both managed by the same management company, Neuberger Berman AIFM Limited.

NB Aurora

NB Aurora, the first permanent capital vehicle listed in Italy on the MIV professional segment of the Italian Stock Exchange, has been created with the purpose to invest in unlisted SMEs, providing financial resources to support their growth and international expansion, thus helping to support the real economy. NB Aurora is promoted by Neuberger Berman, private, independent, employee-owned investment manager, with \$315 billion AUM (as of September 30, 2018).

NB Aurora's investment targets include SMEs with a leading position in specialized niches and a strong export attitude with a turnover between €30 million and €300 million. The NB Aurora team will take an active minority approach, to partner with entrepreneurs with a medium-long term horizon. NB Aurora currently has a portfolio of nine Italian SMEs with an aggregate turnover of approximately €1.1 billion.

General Medical Merate

General Medical Merate (GMM), founded in 1952 in Seriate (Bergamo), produces and sells advanced radiological equipments, such as high technology remote-controlled tables, sophisticated hanging machines, complete radiological rooms and monoblocks, selling its products both under its own brand and as a supplier of the most important multinationals. The fields of application concern both conventional "static" radiology (single images) and "dynamic" radiology (moving images).

For further information on NB Aurora:

Image Building

Cristina Fossati, Luisella Murtas, Laura Filosi

Tel. +39 02 89011 300

Email nb@imagebuilding.it

This document is addressed to professional clients only.

Neuberger Berman Europe Limited is authorised and regulated by the Financial Conduct Authority and is registered in England and Wales, at Lansdowne House, 57 Berkeley Square, London, W1J 6ER and is also a Registered Investment Adviser with the Securities and Exchange Commission in the U.S. and regulated by the Dubai Financial Services Authority. NB Aurora S.A. SICAF-RAIF is reserved alternative investment fund (RAIF) in the form of an investment company with fixed capital (société d'investissement à capital fixe capital SICAF) as per the Luxembourg law of 26 July 2016 on reserved alternative investment funds.

The information in this document does not constitute investment advice or an investment recommendation and is only a brief summary of certain key aspects of the fund.

An investment in the fund involves risks, with the potential for above average risk, and is only suitable for people who are in a position to take such risks. For more information please read the prospectus and principal fund documents.

In relation to each member state of the EEA (each a "Member State"), this document may only be distributed and shares may only be offered or placed in a Member State to the extent that: (1) the fund is permitted to be marketed to professional investors in the relevant Member State in accordance with AIFMD (as implemented into the local law/regulation of the relevant Member State); or (2) this document may otherwise be lawfully distributed and the shares may otherwise be lawfully offered or placed in that Member State (including at the initiative of the investor). In relation to each Member State of the EEA which, at the date of this document, has not implemented AIFMD, this document may only be distributed and shares may only be offered or placed to the extent that this document may be lawfully distributed and the shares may lawfully be offered or placed in that Member State (including at the initiative of the investor).

Germany: Shares of the fund may in particular not be distributed or marketed in any way to German retail or semi-professional investors if the fund is not admitted for distribution to these investor categories by the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht).

United Kingdom: This document is directed only at persons who are professional clients or eligible counterparties for the purposes of the FCA's Conduct of Business Sourcebook. The opportunity to invest in the Fund is only available to such persons in the United Kingdom and this document must not be relied or acted upon by any other persons in the United Kingdom.

Switzerland: The distribution of this fund in Switzerland will be exclusively made to, and directed at, qualified investors ("Qualified Investors"), as defined in the Swiss Collective Investment Schemes Act of 23 June 2006, as amended ("CISA") and its implementing ordinance, the Collective Investment Schemes Ordinance of 22 November 2006, as amended ("CISO"). Accordingly, the fund has not been and will not be registered with the Swiss Financial Market Supervisory Authority ("FINMA"). This document and/or any other offering materials relating to the fund may be made available in Switzerland solely to Qualified Investors. The fund is domiciled in Luxembourg. The Swiss representative is FIRST INDEPENDENT FUND SERVICES LTD, Klausstrasse 33, CH - 8008 Zurich and the Swiss paying agent is Neue Helvetische Bank AG, Seefeldstrasse 215, CH-8008 Zurich. The principal fund documents may be obtained free of charge at the registered office of the Swiss representative. In respect to the shares in the fund distributed to Qualified Investors in Switzerland, the place of performance and the place of jurisdiction is at the Swiss representative's registered office.

This document is presented solely for information purposes and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security.

We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such.

No recommendation or advice is being given as to whether any investment or strategy is suitable for a particular investor. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of any investment, and should consult its own legal counsel and financial, actuarial, accounting, regulatory and tax advisers to evaluate any such investment.

It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable.

Any views or opinions expressed may not reflect those of the firm as a whole.

All information is current as of the date of this material and is subject to change without notice.

The fund described in this document may only be offered for sale or sold in jurisdictions in which or to persons to which such an offer or sale is permitted. The fund can only be promoted if such promotion is made in compliance with the applicable jurisdictional rules and regulations. This document and the information contained therein may not be distributed in the US.

Past performance is not a reliable indicator of current or future results. The value of investments may go down as well as up and investors may not get back any of the amount invested. The performance data does not take account of the commissions and costs incurred on the issue and redemption of units.

The value of investments designated in another currency may rise and fall due to exchange rate fluctuations in respect of the relevant currencies. Adverse movements in currency exchange rates can result in a decrease in return and a loss of capital.

No part of this document may be reproduced in any manner without prior written permission of Neuberger Berman Europe Limited.

The “Neuberger Berman” name and logo are registered service marks of Neuberger Berman Group LLC.
© 2018 Neuberger Berman Group LLC. All rights reserved.